A 12-month phase 3 study of pasireotide in cushing's disease

New England Journal of Medicine

Volumn 366, Issue 10, 2012, Pages 914-924

  Colao, Annamaria ^a   Petersenn, Stephan ^b,c   Newell Price, John ^d   Findling, James W ^e   Gu, Feng ^f   Maldonado, Mario ^g   Schoenherr, Ulrike ^g   Mills, David ^g   Salgado, Luiz Roberto ^h   Biller, Beverly M K ⁱ  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ENDOC Center for Endocrine Tumors   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CORTICOTROPIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYDROCORTISONE; PASIREOTIDE;

ABDOMINAL PAIN; ACTH SECRETING ADENOMA; ADULT; AGED; ALOPECIA; ANXIETY; ARTICLE; ASTHENIA; CHOLELITHIASIS; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERCHOLESTEROLEMIA; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SALIVA LEVEL; SIDE EFFECT; SYNCOPE; TUMOR VOLUME; UPPER ABDOMINAL PAIN;

EID: 84857826594     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1105743     Document Type: Article

References (20)

1. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593-602. (Pubitemid 38033020)
2. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994;40:479-84. (Pubitemid 24194645)
3. Lindholm J, Juul S, Jørgensen JO, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001;86:117-23. (Pubitemid 32111743)
4. Cavagnini F, Pecori Giraldi F. Epidemiology and follow-up of Cushing's disease. Ann Endocrinol (Paris) 2001;62:168-72.
5. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006;367:1605-17. (Pubitemid 43674231)
6. Biller BMK, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454-62. (Pubitemid 352008503)
7. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47. (Pubitemid 36223278)
8. Batista DL, Zhang X, Gejman R, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006;91:4482-8. (Pubitemid 44833427)
9. Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005;152:645-54. (Pubitemid 40575811)
10. van der Hoek J, Waaijers M, van Koetsveld PM, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 2005;289(2):E278-E287. (Pubitemid 41076629)
11. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146:707-16. (Pubitemid 34552506)
12. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009;94:115-22.
13. Webb SM, Badia X, Barahona MJ, et al. Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol 2008;158:623-30. (Pubitemid 351639599)
14. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 3.0. August 9, 2006 (http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf).
15. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol 2010;163:709-16.
16. Lila AR, Gopal RA, Acharya S, et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract 2010;16: 968-76.
17. Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary 2010;13:123-9.
18. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009;94:223-30.
19. Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010;362:1846-8.
20. Henry RR, Mudaliar S, Wetli-Hermosillo K, Ligueros-Saylan M, Chenji S, Golor G. Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Presented at the 13th European Congress of Endocrinology, Rotterdam, the Netherlands, April 30-May 4, 2011. abstract.